In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Utah Medical talks back

This article was originally published in The Gray Sheet

Executive Summary

FDA's public statements "have diminished the company's business through innuendo," by suggesting the firm's alleged QSR non-compliance impacts device safety and effectiveness, Utah Medical charges Aug. 30 in response to an Aug. 9 injunction suit (1"The Gray Sheet" Aug. 16, 2004, p. 6). The manufacturer denies the allegations, which date to 2001. FDA's actions have led competitors to wrongly suggest to customers the firm may be shut down, Utah Medical says. The firm concedes its "total dollar value of orders has remained about normal" in August, but adds that its own 10% customer loyalty discount, instituted Aug. 20, "may have a significant effect on net sales." Utah Medical repurchased about $3.1 mil. of stock between Aug. 1 and Aug. 17...

You may also be interested in...



Utah Medical Upholds Product Safety, Questions FDA Inspector Credentials

Utah Medical Products will challenge during pre-trial discovery whether FDA's inspectional observations of the Midvale, Utah facility can be construed as QSR violations

FDA Slacking In NDI Notification Enforcement; COVID-19 'Is Not An Excuse’ – NPA

In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.

Finance Watch: Four IPOs In One Week, And Legend Is Year’s Largest So Far

Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.

UsernamePublicRestriction

Register

PL000723

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel